[1] 中华医学会消化病学分会肝胆疾病协作组.急性药物性肝损伤诊治建议(草案).中华消化杂志,2007,27:765-767.
[2] 刘盛.临床诊疗指南消化系统疾病分册.北京: 人民卫生出版社,2011, 112-113.
[3] 赖荣陶,王晖,桂红莲,等. 138例药物性肝损伤患者的临床特征及肝脏组织学改变.中华肝脏病杂志,2012,20:185-189.
[4] Duan YF,Sun DL,Chen J,et al.MicroRNA-29a/b/c targets iNOS and is involved in protective remote ischemic preconditioning in an ischemia-reperfusion rat model of non-alcoholic fatty liver disease.Oncol lett,2017,13:1775-1782.
[5] Cerkezkayabekir A,Sanal F,Bakar E,et al.Naringin protects viscera from ischemia/reperfusion injury by regulating the nitric oxide level in a rat model.Biotechnic & histochemistry : official publication of the Biological Stain Commission,2017,92:252-263.
[6] Duan YF, Sun DL, Chen J, et al. MicroRNA-29a/b/c targets iNOS and is involved in protective remote ischemic preconditioning in an ischemia-reperfusion rat model of non-alcoholic fatty liver disease. Oncol Lett, 2017,13:1775-1782.
[7] Iyer MR,Cinar R,Katz A,et al. Design, synthesis, and biological evaluation of novel, non-brain-penetrant, hybrid cannabinoid CB1R inverse agonist/Inducible nitric oxide synthase (iNOS)inhibitors for the treatment of liver fibrosis. J Med Chem, 2017,60:1126-1141.
[8] 王涛,陈东风.多烯磷脂酰胆碱通过过氧化物酶体增殖物激活受体α/肉碱棕榈酰基转移酶1 A通路影响肝细胞脂肪变性.中华肝脏病杂志,2016,24:294-296.
[9] 白贞子,牛俊奇,姜艳芳,等.降脂酮对CCl4所致急慢性肝损伤大鼠肝组织、血清中NO、NOS水平的影响.中国老年学杂志,2009,29:1333-1335. |
